Diagnostic, Prognostic, and Therapeutic Roles of Gut Microbiota in COVID-19: A Comprehensive Systematic Review

Yeganeh Farsi, Azin Tahvildari, Mahta Arbabi, Fateme Vazife, Leonardo A Sechi, Amir Hashem Shahidi Bonjar, Parnian Jamshidi, Mohammad Javad Nasiri, Mehdi Mirsaeidi, Yeganeh Farsi, Azin Tahvildari, Mahta Arbabi, Fateme Vazife, Leonardo A Sechi, Amir Hashem Shahidi Bonjar, Parnian Jamshidi, Mohammad Javad Nasiri, Mehdi Mirsaeidi

Abstract

Introduction: The Coronavirus Disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) emerged in late December 2019. Considering the important role of gut microbiota in maturation, regulation, and induction of the immune system and subsequent inflammatory processes, it seems that evaluating the composition of gut microbiota in COVID-19 patients compared with healthy individuals may have potential value as a diagnostic and/or prognostic biomarker for the disease. Also, therapeutic interventions affecting gut microbial flora may open new horizons in the treatment of COVID-19 patients and accelerating their recovery.

Methods: A systematic search was conducted for relevant studies published from December 2019 to December 2021 using Pubmed/Medline, Embase, and Scopus. Articles containing the following keywords in titles or abstracts were selected: "SARS-CoV-2" or "COVID-19" or "Coronavirus Disease 19" and "gastrointestinal microbes" or "dysbiosis" or "gut microbiota" or "gut bacteria" or "gut microbes" or "gastrointestinal microbiota".

Results: Out of 1,668 studies, 22 articles fulfilled the inclusion criteria and a total of 1,255 confirmed COVID-19 patients were examined. All included studies showed a significant association between COVID-19 and gut microbiota dysbiosis. The most alteration in bacterial composition of COVID-19 patients was depletion in genera Ruminococcus, Alistipes, Eubacterium, Bifidobacterium, Faecalibacterium, Roseburia, Fusicathenibacter, and Blautia and enrichment of Eggerthella, Bacteroides, Actinomyces, Clostridium, Streptococcus, Rothia, and Collinsella. Also, some gut microbiome alterations were associated with COVID-19 severity and poor prognosis including the increment of Bacteroides, Parabacteroides, Clostridium, Bifidobacterium, Ruminococcus, Campylobacter, Rothia, Corynebacterium, Megasphaera, Enterococcus, and Aspergillus spp. and the decrement of Roseburia, Eubacterium, Lachnospira, Faecalibacterium, and the Firmicutes/Bacteroidetes ratio.

Conclusion: Our study showed a significant change of gut microbiome composition in COVID-19 patients compared with healthy individuals. This great extent of impact has proposed the gut microbiota as a potential diagnostic, prognostic, and therapeutic strategy for COVID-19. There is much evidence about this issue, and it is expected to be increased in near future.

Keywords: COVID-19; SARS-CoV-2; diagnosis; dysbiosis; gastrointestinal microbiome; gut microbiota; prognosis; therapeutic.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Farsi, Tahvildari, Arbabi, Vazife, Sechi, Shahidi Bonjar, Jamshidi, Nasiri and Mirsaeidi.

Figures

Figure 1
Figure 1
PRISMA flowchart of study selection for inclusion in the systematic review.

References

    1. Abt M. C., Osborne L. C., Monticelli L. A., Doering T. A., Alenghat T., Sonnenberg G. F., et al. . (2012). Commensal Bacteria Calibrate the Activation Threshold of Innate Antiviral Immunity. Immunity 37 (1), 158–170. doi: 10.1016/j.immuni.2012.04.011
    1. Ahmadi Badi S., Tarashi S., Fateh A., Rohani P., Masotti A., Siadat S. D. (2021). From the Role of Microbiota in Gut-Lung Axis to SARS-CoV-2 Pathogenesis. Mediators Inflamm. 2021, 6611222. doi: 10.1155/2021/6611222
    1. Aktaş B., Aslim B. (2020). Gut-Lung Axis and Dysbiosis in COVID-19. Turkish J. Biol. 44 (SI-1), 265–272. doi: 10.3906/biy-2005-102
    1. Alameddine J., Godefroy E., Papargyris L., Sarrabayrouse G., Tabiasco J., Bridonneau C., et al. . (2019). Faecalibacterium Prausnitzii Skews Human DC to Prime IL10-Producing T Cells Through TLR2/6/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction. Front. Immunol. 10, 143. doi: 10.3389/fimmu.2019.00143
    1. Alexander M., Ang Q. Y., Turnbaugh P. J. (2019). A Diet-Dependent Enzyme From the Human Gut Microbiome Promotes Th17 Accumulation and Colitis. bioRxiv Preprint Server Biol., 766899. doi: 10.1101/766899
    1. Allali I., Bakri Y., Amzazi S., Ghazal H. (2021). Gut-Lung Axis in COVID-19. Interdiscip. Perspect. Infect. Dis. 2021, 6655380. doi: 10.1155/2021/6655380
    1. Alvarez C. A., Jones M. B., Hambor J., Cobb B. A. (2020). Characterization of Polysaccharide A Response Reveals Interferon Responsive Gene Signature and Immunomodulatory Marker Expression. Front. Immunol. 11 (2677). doi: 10.3389/fimmu.2020.556813
    1. Antosca K. M., Chernikova D. A., Price C. E., Ruoff K. L., Li K., Guill M. F., et al. . (2019). Altered Stool Microbiota of Infants With Cystic Fibrosis Shows a Reduction in Genera Associated With Immune Programming From Birth. J. Bacteriol. 201 (16), e00274–e00219. doi: 10.1128/JB.00274-19
    1. Antunes K. H., Fachi J. L., de Paula R., da Silva E. F., Pral L. P., Dos Santos A., et al. . (2019). Microbiota-Derived Acetate Protects Against Respiratory Syncytial Virus Infection Through a GPR43-Type 1 Interferon Response. Nat. Commun. 10 (1), 3273. doi: 10.1038/s41467-019-11152-6
    1. Arenas-Padilla M., González-Rascón A., Hernández-Mendoza A., Calderón de la Barca A. M., Hernández J., Mata-Haro V. (2021). Immunomodulation by Bifidobacterium Animalis Subsp. Lactis Bb12: Integrative Analysis of miRNA Expression and TLR2 Pathway-Related Target Proteins in Swine Monocytes. Probiot. Antimicrob. Proteins 20, 1–13. doi: 10.1007/s12602-021-09816-1
    1. Avery E. G., Bartolomaeus H., Maifeld A., Marko L., Wiig H., Wilck N., et al. . (2021). The Gut Microbiome in Hypertension: Recent Advances and Future Perspectives. Circ. Res. 128 (7), 934–950. doi: 10.1161/CIRCRESAHA.121.318065
    1. Battaglini D., Robba C., Fedele A., Trancǎ S., Sukkar S. G., Di Pilato V., et al. . (2021). The Role of Dysbiosis in Critically Ill Patients With COVID-19 and Acute Respiratory Distress Syndrome. Front. Med. 8, 671714. doi: 10.3389/fmed.2021.671714
    1. Belizário J. E., Faintuch J., Garay-Malpartida M. (2018). Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases. Mediators Inflamm. 2018, 2037838. doi: 10.1155/2018/2037838
    1. Bhushan I., Sharma M., Mehta M., Badyal S., Sharma V., Sharma I., et al. . (2021). Bioactive Compounds and Probiotics–a Ray of Hope in COVID-19 Management. Food Sci. Hum. Wellness 10 (2), 131–140. doi: 10.1016/j.fshw.2021.02.001
    1. Boursier J., Mueller O., Barret M., Machado M., Fizanne L., Araujo-Perez F., et al. . (2016). The Severity of Nonalcoholic Fatty Liver Disease is Associated With Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota. Hepatology 63 (3), 764–775. doi: 10.1002/hep.28356
    1. Bozkurt H. S., Kara B. (2020). A New Treatment for Ulcerative Colitis: Intracolonic Bifidobacterium and Xyloglucan Application. Eur. J. Inflamm. 18, 2058739220942626. doi: 10.1177/2058739220942626
    1. Bozkurt H. S., Quigley E. M. (2020. a). The Probiotic Bifidobacterium in the Management of Coronavirus: A Theoretical Basis. Int. J. Immunopathol. Pharmacol. 34, 2058738420961304. doi: 10.1177/2058738420961304
    1. Bozkurt H., Quigley E. (2020. b). Probiotic Bifidobacteria Against the COVİD-19: A New Way Out! Int. J. Immunopathol. Pharmacol. 34. doi: 10.1177/2058738420961304
    1. Bozkurt H. S., Quigley E. M., Kara B. (2019). Bifidobacterium Animalis Subspecies Lactis Engineered to Produce Mycosporin-Like Amino Acids in Colorectal Cancer Prevention. SAGE Open Med. 7, 2050312119825784. doi: 10.1177/2050312119825784
    1. Brown R. L., Sequeira R. P., Clarke T. B. (2017). The Microbiota Protects Against Respiratory Infection via GM-CSF Signaling. Nat. Commun. 8 (1), 1512. doi: 10.1038/s41467-017-01803-x
    1. Budden K. F., Gellatly S. L., Wood D. L., Cooper M. A., Morrison M., Hugenholtz P., et al. . (2017). Emerging Pathogenic Links Between Microbiota and the Gut-Lung Axis. Nat. Rev. Microbiol. 15 (1), 55–63. doi: 10.1038/nrmicro.2016.142
    1. Cao J., Wang C., Zhang Y., Lei G., Xu K., Zhao N., et al. . (2021). Integrated Gut Virome and Bacteriome Dynamics in COVID-19 Patients. Gut Microbes 13 (1), 1887722. doi: 10.1080/19490976.2021.1887722
    1. Chakraborty K., Raundhal M., Chen B. B., Morse C., Tyurina Y. Y., Khare A., et al. . (2017). The Mito-DAMP Cardiolipin Blocks IL-10 Production Causing Persistent Inflammation During Bacterial Pneumonia. Nat. Commun. 8, 13944. doi: 10.1038/ncomms13944
    1. Chattopadhyay I., Shankar E. M. (2021). SARS-CoV-2-Indigenous Microbiota Nexus: Does Gut Microbiota Contribute to Inflammation and Disease Severity in COVID-19? Front. Cell. Infect. Microbiol. 11 (96). doi: 10.3389/fcimb.2021.590874
    1. Chen J., Vitetta L. (2021). Modulation of Gut Microbiota for the Prevention and Treatment of COVID-19. J. Clin. Med. 10 (13), 2903. doi: 10.3390/jcm10132903
    1. Chhibber-Goel J., Gopinathan S., Sharma A. (2021). Interplay Between Severities of COVID-19 and the Gut Microbiome: Implications of Bacterial Co-Infections? Gut Pathogens 13 (1), 14. doi: 10.1186/s13099-021-00407-7
    1. Claesson M. J., Jeffery I. B., Conde S., Power S. E., O’Connor E. M., Cusack S., et al. . (2012). Gut Microbiota Composition Correlates With Diet and Health in the Elderly. Nature 488 (7410), 178–184. doi: 10.1038/nature11319
    1. Crovesy L., Masterson D., Rosado E. L. (2020). Profile of the Gut Microbiota of Adults With Obesity: A Systematic Review. Eur. J. Clin. Nutr. 74 (9), 1251–1262. doi: 10.1038/s41430-020-0607-6
    1. Cyprian F., Sohail M. U., Abdelhafez I., Salman S., Attique Z., Kamareddine L., et al. . (2021). SARS-CoV-2 and Immune-Microbiome Interactions: Lessons From Respiratory Viral Infections. Int. J. Infect. Dis. 105, 540–550. doi: 10.1016/j.ijid.2021.02.071
    1. D’Amico F., Baumgart D. C., Danese S., Peyrin-Biroulet L. (2020). Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin. Gastroenterol. Hepatol. 18 (8), 1663–1672. doi: 10.1016/j.cgh.2020.04.001
    1. Dang A. T., Marsland B. J. (2019). Microbes, Metabolites, and the Gut-Lung Axis. Mucosal Immunol. 12 (4), 843–850. doi: 10.1038/s41385-019-0160-6
    1. d’Ettorre G., Ceccarelli G., Marazzato M., Campagna G., Pinacchio C., Alessandri F., et al. . (2020). Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. Front. Med. 7, 389. doi: 10.3389/fmed.2020.00389
    1. de Vrese M., Winkler P., Rautenberg P., Harder T., Noah C., Laue C., et al. . (2005). Effect of Lactobacillus Gasseri PA 16/8, Bifidobacterium Longum SP 07/3, B. Bifidum MF 20/5 on Common Cold Episodes: A Double Blind, Randomized, Controlled Trial. Clin. Nutr. (Edinburgh Scotland) 24 (4), 481–491. doi: 10.1016/j.clnu.2005.02.006
    1. Dickson R. P., Huffnagle G. B. (2015). The Lung Microbiome: New Principles for Respiratory Bacteriology in Health and Disease. PloS Pathogens 11 (7), e1004923. doi: 10.1371/journal.ppat.1004923
    1. Din A. U., Mazhar M., Waseem M., Ahmad W., Bibi A., Hassan A., et al. . (2021). SARS-CoV-2 Microbiome Dysbiosis Linked Disorders and Possible Probiotics Role. Biomed. Pharmacother. = Biomed. Pharmacother. 133, 110947. doi: 10.1016/j.biopha.2020.110947
    1. Donaldson G. P., Lee S. M., Mazmanian S. K. (2016). Gut Biogeography of the Bacterial Microbiota. Nat. Rev. Microbiol. 14 (1), 20–32. doi: 10.1038/nrmicro3552
    1. Donati Zeppa S., Agostini D., Piccoli G., Stocchi V., Sestili P. (2020). Gut Microbiota Status in COVID-19: An Unrecognized Player? Front. Cell. Infect. Microbiol. 10 (742). doi: 10.3389/fcimb.2020.576551
    1. Enaud R., Prevel R., Ciarlo E., Beaufils F., Wieërs G., Guery B., et al. . (2020). The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and Inter-Kingdom Crosstalks. Front. Cell. Infect. Microbiol. 10 (9). doi: 10.3389/fcimb.2020.00009
    1. Fagundes C. T., Amaral F. A., Vieira A. T., Soares A. C., Pinho V., Nicoli J. R., et al. . (2012). Transient TLR Activation Restores Inflammatory Response and Ability to Control Pulmonary Bacterial Infection in Germfree Mice. J. Immunol. (Baltimore Md 1950) 188 (3), 1411–1420. doi: 10.4049/jimmunol.1101682
    1. Ferreira E., Penna B., Yates E. A. (2020). Should We Be Worried About Clostridioides Difficile During the SARS-CoV2 Pandemic? Front. Microbiol. 11 (2292). doi: 10.3389/fmicb.2020.581343
    1. Fox A. C., McConnell K. W., Yoseph B. P., Breed E., Liang Z., Clark A. T., et al. . (2012). The Endogenous Bacteria Alter Gut Epithelial Apoptosis and Decrease Mortality Following Pseudomonas Aeruginosa Pneumonia. Shock (Augusta Ga) 38 (5), 508–514. doi: 10.1097/SHK.0b013e31826e47e8
    1. Gaibani P., D’Amico F., Bartoletti M., Lombardo D., Rampelli S., Fornaro G., et al. . (2021). The Gut Microbiota of Critically Ill Patients With COVID-19. Front. Cell. Infect. Microbiol. 11 (554). doi: 10.3389/fcimb.2021.670424
    1. Gao J., Xu K., Liu H., Liu G., Bai M., Peng C., et al. . (2018). Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism. Front. Cell. Infect. Microbiol. 8, 13. doi: 10.3389/fcimb.2018.00013
    1. Gautier T., David-Le Gall S., Sweidan A., Tamanai-Shacoori Z., Jolivet-Gougeon A., Loréal O., et al. . (2021). Next-Generation Probiotics and Their Metabolites in COVID-19. Microorganisms 9 (5), 941. doi: 10.3390/microorganisms9050941
    1. Geva-Zatorsky N., Sefik E., Kua L., Pasman L., Tan T. G., Ortiz-Lopez A., et al. . (2017). Mining the Human Gut Microbiota for Immunomodulatory Organisms. Cell 168 (5), 928–943.e11. doi: 10.1016/j.cell.2017.01.022
    1. Groeger D., O’Mahony L., Murphy E. F., Bourke J. F., Dinan T. G., Kiely B., et al. . (2013). Bifidobacterium Infantis 35624 Modulates Host Inflammatory Processes Beyond the Gut. Gut Microbes 4 (4), 325–339. doi: 10.4161/gmic.25487
    1. Gu J., Han B., Wang J. (2020. a). COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology 158 (6), 1518–1519. doi: 10.1053/j.gastro.2020.02.054
    1. Gu S., Chen Y., Wu Z., Chen Y., Gao H., Lv L., et al. . (2020. b). Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza. Clin. Infect. Dis. 71 (10), 2669–2678. doi: 10.1093/cid/ciaa709
    1. Haak B. W., Littmann E. R., Chaubard J. L., Pickard A. J., Fontana E., Adhi F., et al. . (2018). Impact of Gut Colonization With Butyrate-Producing Microbiota on Respiratory Viral Infection Following Allo-HCT. Blood 131 (26), 2978–2986. doi: 10.1182/blood-2018-01-828996
    1. Hall A. B., Yassour M., Sauk J., Garner A., Jiang X., Arthur T., et al. . (2017). A Novel Ruminococcus Gnavus Clade Enriched in Inflammatory Bowel Disease Patients. Genome Med. 9 (1), 103. doi: 10.1186/s13073-017-0490-5
    1. Han C., Ding Z., Shi H., Qian W., Hou X., Lin R. (2016). The Role of Probiotics in Lipopolysaccharide-Induced Autophagy in Intestinal Epithelial Cells. Cell. Physiol. Biochem. 38 (6), 2464–2478. doi: 10.1159/000445597
    1. Han Y., Jia Z., Shi J., Wang W., He K. (2020). The Active Lung Microbiota Landscape of COVID-19 Patients. medRxiv. doi: 10.1101/2020.08.20.20144014
    1. Harmer D., Gilbert M., Borman R., Clark K. L. (2002). Quantitative mRNA Expression Profiling of ACE 2, a Novel Homologue of Angiotensin Converting Enzyme. FEBS Lett. 532 (1-2), 107–110. doi: 10.1016/S0014-5793(02)03640-2
    1. Hegazy M., Ahmed Ashoush O., Tharwat Hegazy M., Wahba M., Lithy R. M., Abdel-Hamid H. M., et al. . (2021). Beyond Probiotic Legend: ESSAP Gut Microbiota Health Score to Delineate SARS-COV-2 Infection Severity. Br. J. Nutr. 7, 1–10. doi: 10.1017/S0007114521001926
    1. Henke M. T., Kenny D. J., Cassilly C. D., Vlamakis H., Xavier R. J., Clardy J. (2019). Ruminococcus Gnavus, a Member of the Human Gut Microbiome Associated With Crohn’s Disease, Produces an Inflammatory Polysaccharide. Proc. Natl. Acad. Sci. U. S. A. 116 (26), 12672–12677. doi: 10.1073/pnas.1904099116
    1. He Y., Wang J., Li F., Shi Y. (2020). Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2 Infections. Front. Microbiol. 11, 1302. doi: 10.3389/fmicb.2020.01302
    1. He Y., Wen Q., Yao F., Xu D., Huang Y., Wang J. (2017). Gut-Lung Axis: The Microbial Contributions and Clinical Implications. Crit. Rev. Microbiol. 43 (1), 81–95. doi: 10.1080/1040841X.2016.1176988
    1. He F., Zhang T., Xue K., Fang Z., Jiang G., Huang S., et al. . (2021). Fecal Multi-Omics Analysis Reveals Diverse Molecular Alterations of Gut Ecosystem in COVID-19 Patients. Analyt. Chim. Acta 1180, 338881. doi: 10.1016/j.aca.2021.338881
    1. Hong N., Ku S., Yuk K., Johnston T. V., Ji G. E., Park M. S. (2021). Production of Biologically Active Human Interleukin-10 by Bifidobacterium Bifidum BGN4. Microb. Cell Fact. 20 (1), 16. doi: 10.1186/s12934-020-01505-y
    1. Howell M. C., Green R., McGill A. R., Dutta R., Mohapatra S., Mohapatra S. S. (2021). SARS-CoV-2-Induced Gut Microbiome Dysbiosis: Implications for Colorectal Cancer. Cancers 13 (11), 2676. doi: 10.3390/cancers13112676
    1. Hussain I., Cher G. L. Y., Abid M. A., Abid M. B. (2021). Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential. Front. Immunol. 12. doi: 10.3389/fimmu.2021.765965
    1. Huynh K. (2020). Novel Gut Microbiota-Derived Metabolite Promotes Platelet Thrombosis via Adrenergic Receptor Signalling. Nat. Rev. Cardiol. 17 (5), 265. doi: 10.1038/s41569-020-0367-y
    1. Ichinohe T., Pang I. K., Kumamoto Y., Peaper D. R., Ho J. H., Murray T. S., et al. . (2011). Microbiota Regulates Immune Defense Against Respiratory Tract Influenza A Virus Infection. Proc. Natl. Acad. Sci. U. S. A. 108 (13), 5354–5359. doi: 10.1073/pnas.1019378108
    1. Jamshidi P., Hajikhani B., Mirsaeidi M., Vahidnezhad H., Dadashi M., Nasiri M. J. (2021). Skin Manifestations in COVID-19 Patients: Are They Indicators for Disease Severity? A Systematic Review. Front. Med. 8, 634208. doi: 10.3389/fmed.2021.634208
    1. Jamshidi P., Hasanzadeh S., Tahvildari A., Farsi Y., Arbabi M., Mota J. F., et al. . (2019). Is There Any Association Between Gut Microbiota and Type 1 Diabetes? A Systematic Review. Gut Pathog. 11 (1), 49. doi: 10.1186/s13099-019-0332-7
    1. Jia W., Xie G., Jia W. (2018). Bile Acid–Microbiota Crosstalk in Gastrointestinal Inflammation and Carcinogenesis. Nat. Rev. Gastroenterol. Hepatol. 15 (2), 111–128. doi: 10.1038/nrgastro.2017.119
    1. Joanna Briggs Institute . (2021). Critical Appraisal Tools (South Australia: Joanna Briggs Institute: University of Adelaide; ). Available at: .
    1. Juárez-Fernández M., Porras D., García-Mediavilla M. V., Román-Sagüillo S., González-Gallego J., Nistal E., et al. . (2021). Aging, Gut Microbiota and Metabolic Diseases: Management Through Physical Exercise and Nutritional Interventions. Nutrients 13 (1), 16. doi: 10.3390/nu13010016
    1. Jungersen M., Wind A., Johansen E., Christensen J. E., Stuer-Lauridsen B., Eskesen D. (2014). The Science Behind the Probiotic Strain Bifidobacterium Animalis Subsp. lactis BB-12(®). Microorganisms 2 (2), 92–110. doi: 10.3390/microorganisms2020092
    1. Kalinkovich A., Livshits G. (2019). A Cross Talk Between Dysbiosis and Gut-Associated Immune System Governs the Development of Inflammatory Arthropathies. Semin. Arthritis Rheum. 49 (3), 474–484. doi: 10.1016/j.semarthrit.2019.05.007
    1. Katz-Agranov N., Zandman-Goddard G. (2021). Autoimmunity and COVID-19 - The Microbiotal Connection. Autoimmun. Rev. 20 (8), 102865. doi: 10.1016/j.autrev.2021.102865
    1. Khan M., Mathew B. J., Gupta P., Garg G., Khadanga S., Vyas A. K., et al. . (2021). Gut Dysbiosis and IL-21 Response in Patients With Severe COVID-19. Microorganisms 9 (6), 1292. doi: 10.3390/microorganisms9061292
    1. Khanna S., Kraft C. S. (2021). The Interplay of SARS-CoV-2 and Clostridioides Difficile Infection. Future Microbiol. 16 (6), 439–443. doi: 10.2217/fmb-2020-0275
    1. Kim H.-N., Joo E.-J., Lee C.-W., Ahn K.-S., Kim H.-L., Park D.-I., et al. . (2021). Reversion of Gut Microbiota During the Recovery Phase in Patients With Asymptomatic or Mild COVID-19: Longitudinal Study. Microorganisms 9 (6), 1237. doi: 10.3390/microorganisms9061237
    1. King S., Glanville J., Sanders M. E., Fitzgerald A., Varley D. (2014). Effectiveness of Probiotics on the Duration of Illness in Healthy Children and Adults Who Develop Common Acute Respiratory Infectious Conditions: A Systematic Review and Meta-Analysis. Br. J. Nutr. 112 (1), 41–54. doi: 10.1017/S0007114514000075
    1. Koh A., De Vadder F., Kovatcheva-Datchary P., Bäckhed F. (2016). From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell 165 (6), 1332–1345. doi: 10.1016/j.cell.2016.05.041
    1. Kyo M., Nishioka K., Nakaya T., Kida Y., Tanabe Y., Ohshimo S., et al. . (2019). Unique Patterns of Lower Respiratory Tract Microbiota are Associated With Inflammation and Hospital Mortality in Acute Respiratory Distress Syndrome. Respir. Res. 20 (1), 246. doi: 10.1186/s12931-019-1203-y
    1. Kyriakidou A., Koufakis T., Goulis D. G., Vasilopoulos Y., Zebekakis P., Kotsa K. (2021). Pharmacogenetics of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management. Curr. Pharm. Des. 27 (8), 1025–1034. doi: 10.2174/1381612826666201203145654
    1. Lamers M. M., Beumer J., van der Vaart J., Knoops K., Puschhof J., Breugem T. I., et al. . (2020). SARS-CoV-2 Productively Infects Human Gut Enterocytes. Sci. (New York NY) 369 (6499), 50–54. doi: 10.1126/science.abc1669
    1. Larsen N., Vogensen F. K., van den Berg F. W., Nielsen D. S., Andreasen A. S., Pedersen B. K., et al. . (2010). Gut Microbiota in Human Adults With Type 2 Diabetes Differs From non-Diabetic Adults. PloS One 5 (2), e9085. doi: 10.1371/journal.pone.0009085
    1. Ley R. E., Turnbaugh P. J., Klein S., Gordon J. I. (2006). Human Gut Microbes Associated With Obesity. Nature 444 (7122), 1022–1023. doi: 10.1038/4441022a
    1. Li W., Moore M. J., Vasilieva N., Sui J., Wong S. K., Berne M. A., et al. . (2003). Angiotensin-Converting Enzyme 2 is a Functional Receptor for the SARS Coronavirus. Nature 426 (6965), 450–454. doi: 10.1038/nature02145
    1. Liu F., Ye S., Zhu X., He X., Wang S., Li Y., et al. . (2021). Gastrointestinal Disturbance and Effect of Fecal Microbiota Transplantation in Discharged COVID-19 Patients. J. Med. Case Rep. 15 (1), 60. doi: 10.1186/s13256-020-02583-7
    1. Lv L., Gu S., Jiang H., Yan R., Chen Y., Chen Y., et al. . (2021. b). Gut Mycobiota Alterations in Patients With COVID-19 and H1N1 Infections and Their Associations With Clinical Features. Commun. Biol. 4 (1), 480. doi: 10.1038/s42003-021-02036-x
    1. Lv L., Jiang H., Chen Y., Gu S., Xia J., Zhang H., et al. . (2021. a). The Faecal Metabolome in COVID-19 Patients is Altered and Associated With Clinical Features and Gut Microbes. Analyt. Chim. Acta 1152, 338267. doi: 10.1016/j.aca.2021.338267
    1. Massip Copiz M. M. (2021). The Gut Microbiota in Patients With COVID-19 and Obesity. FASEB J. 35 (S1). doi: 10.1096/fasebj.2021.35.S1.05159
    1. Matsuoka K., Kanai T. (Eds.) (2015). The Gut Microbiota and Inflammatory Bowel Disease. Seminars in Immunopathology (Springer; ).
    1. Milner E., Stevens B., An M., Lam V., Ainsworth M., Dihle P., et al. . (2021). Utilizing Probiotics for the Prevention and Treatment of Gastrointestinal Diseases. Front. Microbiol. 12, 689958. doi: 10.3389/fmicb.2021.689958
    1. Mineshita Y., Sasaki H., H-k K., Shibata S. (2021). Relationship Between Fasting and Postprandial Glucose Levels and the Gut Microbiota, 24 September 2021, PREPRINT (Version 1). available at Research Square []
    1. Minot S., Sinha R., Chen J., Li H., Keilbaugh S. A., Wu G. D., et al. . (2011). The Human Gut Virome: Inter-Individual Variation and Dynamic Response to Diet. Genome Res. 21 (10), 1616–1625. doi: 10.1101/gr.122705.111
    1. Moher D., Liberati A., Tetzlaff J., Altman D. G. (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann. Internal Med. 151 (4), 264–269. doi: 10.7326/0003-4819-151-4-200908180-00135
    1. Mohseni A. H., Casolaro V., Bermúdez-Humarán L. G., Keyvani H., Taghinezhad S. S. (2021). Modulation of the PI3K/Akt/mTOR Signaling Pathway by Probiotics as a Fruitful Target for Orchestrating the Immune Response. Gut Microbes 13 (1), 1–17. doi: 10.1080/19490976.2021.1886844
    1. Moreira-Rosário A., Marques C., Pinheiro H., Araújo J. R., Ribeiro P., Rocha R., et al. . (2021). Gut Microbiota Diversity and C-Reactive Protein Are Predictors of Disease Severity in COVID-19 Patients. Front. Microbiol. 12, 705020. doi: 10.3389/fmicb.2021.705020
    1. Oba J., Silva C. A., Toma R. K., Carvalho W. B., Delgado A. F. (2020). COVID-19 and Coinfection With Clostridioides (Clostridium) Difficile in an Infant With Gastrointestinal Manifestation. Einstein (Sao Paulo Brazil) 18, eRC6048. doi: 10.31744/einstein_journal/2020RC6048
    1. O’Toole P. W., Jeffery I. B. (2018). Microbiome-Health Interactions in Older People. Cell. Mol. Life Sci. 75 (1), 119–128. doi: 10.1007/s00018-017-2673-z
    1. Patel K. P., Patel P. A., Vunnam R. R., Hewlett A. T., Jain R., Jing R., et al. . (2020). Gastrointestinal, Hepatobiliary, and Pancreatic Manifestations of COVID-19. J. Clin. Virol. 128, 104386. doi: 10.1016/j.jcv.2020.104386
    1. Prasad R., Patton M. J., Floyd J. L., Vieira C. P., Fortmann S., DuPont M., et al. . (2021). Plasma Microbiome in COVID-19 Subjects: An Indicator of Gut Barrier Defects and Dysbiosis. bioRxiv Preprint Server Biol. 33851159. doi: 10.1101/2021.04.06.438634
    1. Rahayu E. S., Utami T., Mariyatun M., Hasan P. N., Kamil R. Z., Setyawan R. H., et al. . (2019). Gut Microbiota Profile in Healthy Indonesians. World J. Gastroenterol. 25 (12), 1478–1491. doi: 10.3748/wjg.v25.i12.1478
    1. Rajput S., Paliwal D., Naithani M., Kothari A., Meena K., Rana S. (2021). COVID-19 and Gut Microbiota: A Potential Connection. Indian J. Clin. Biochem. 36 (3), 1–12. doi: 10.1007/s12291-020-00948-9
    1. Ramakrishna C., Kujawski M., Chu H., Li L., Mazmanian S. K., Cantin E. M. (2019). Bacteroides Fragilis Polysaccharide A Induces IL-10 Secreting B and T Cells That Prevent Viral Encephalitis. Nat. Commun. 10 (1), 2153. doi: 10.1038/s41467-019-09884-6
    1. Reyes A., Semenkovich N. P., Whiteson K., Rohwer F., Gordon J. I. (2012). Going Viral: Next-Generation Sequencing Applied to Phage Populations in the Human Gut. Nat. Rev. Microbiol. 10 (9), 607–617. doi: 10.1038/nrmicro2853
    1. Rokkam V. R. P., Kutti G., Sridharan, Vegunta R., Vegunta R., Boregowda U., Mohan B. P. (2021). Clostridium Difficile and COVID-19: Novel Risk Factors for Acute Portal Vein Thrombosis. Case Rep. Vasc. Med. 2021, 8832638. doi: 10.1155/2021/8832638
    1. Salazar N., Valdés-Varela L., González S., Gueimonde M., de Los Reyes-Gavilán C. G. (2017). Nutrition and the Gut Microbiome in the Elderly. Gut Microbes 8 (2), 82–97. doi: 10.1080/19490976.2016.1256525
    1. Sandhu A., Tillotson G., Polistico J., Salimnia H., Cranis M., Moshos J., et al. . (2020). Clostridioides Difficile in COVID-19 Patients, Detroit, Michigan, USA, March-April 2020. Emerg. Infect. Dis. 26 (9), 2272–2274. doi: 10.3201/eid2609.202126
    1. Schett G., Sticherling M., Neurath M. F. (2020). COVID-19: Risk for Cytokine Targeting in Chronic Inflammatory Diseases? Nat. Rev. Immunol. 20 (5), 271–272. doi: 10.1038/s41577-020-0312-7
    1. Schiavi E., Gleinser M., Molloy E., Groeger D., Frei R., Ferstl R., et al. . (2016). The Surface-Associated Exopolysaccharide of Bifidobacterium Longum 35624 Plays an Essential Role in Dampening Host Proinflammatory Responses and Repressing Local TH17 Responses. Appl. Environ. Microbiol. 82 (24), 7185–7196. doi: 10.1128/AEM.02238-16
    1. Schirmer M., Smeekens S. P., Vlamakis H., Jaeger M., Oosting M., Franzosa E. A., et al. . (2016). Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. Cell 167 (4), 1125–1136.e8. doi: 10.1016/j.cell.2016.10.020
    1. Segal J. P., Mak J. W. Y., Mullish B. H., Alexander J. L., Ng S. C., Marchesi J. R. (2020). The Gut Microbiome: An Under-Recognised Contributor to the COVID-19 Pandemic? Ther. Adv. Gastroenterol. 13, 1756284820974914. doi: 10.1177/1756284820974914
    1. Sokol H., Pigneur B., Watterlot L., Lakhdari O., Bermúdez-Humarán L. G., Gratadoux J.-J., et al. . (2008). Faecalibacterium Prausnitzii is an Anti-Inflammatory Commensal Bacterium Identified by Gut Microbiota Analysis of Crohn Disease Patients. Proc. Natl. Acad. Sci. 105 (43), 16731–16736. doi: 10.1073/pnas.0804812105
    1. Suárez-Fariñas M., Tokuyama M., Wei G., Huang R., Livanos A., Jha D., et al. . (2021). Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2-Related Disease. Gastroenterology 160 (1), 287–301.e20. doi: 10.1053/j.gastro.2020.09.029
    1. Tang L., Gu S., Gong Y., Li B., Lu H., Li Q., et al. . (2020). Clinical Significance of the Correlation Between Changes in the Major Intestinal Bacteria Species and COVID-19 Severity. Eng. (Beijing China) 6 (10), 1178–1184. doi: 10.1016/j.eng.2020.05.013
    1. Tao W., Zhang G., Wang X., Guo M., Zeng W., Xu Z., et al. . (2020). Analysis of the Intestinal Microbiota in COVID-19 Patients and its Correlation With the Inflammatory Factor IL-18. Med. Microecol. 5, 100023. doi: 10.1016/j.medmic.2020.100023
    1. Tian T., Zhao Y., Yang Y., Wang T., Jin S., Guo J., et al. . (2020). The Protective Role of Short-Chain Fatty Acids Acting as Signal Molecules in Chemotherapy- or Radiation-Induced Intestinal Inflammation. Am. J. Cancer Res. 10 (11), 3508–3531.
    1. Trompette A., Gollwitzer E. S., Pattaroni C., Lopez-Mejia I. C., Riva E., Pernot J., et al. . (2018). Dietary Fiber Confers Protection Against Flu by Shaping Ly6c(-) Patrolling Monocyte Hematopoiesis and CD8(+) T Cell Metabolism. Immunity 48 (5), 992–1005.e8. doi: 10.1016/j.immuni.2018.04.022
    1. Turnbaugh P. J., Ley R. E., Mahowald M. A., Magrini V., Mardis E. R., Gordon J. I. (2006). An Obesity-Associated Gut Microbiome With Increased Capacity for Energy Harvest. Nature 444 (7122), 1027–1031. doi: 10.1038/nature05414
    1. van den Munckhof I. C., Kurilshikov A., ter Horst R., Riksen N. P., Joosten L., Zhernakova A., et al. . (2018). Role of Gut Microbiota in Chronic Low-Grade Inflammation as Potential Driver for Atherosclerotic Cardiovascular Disease: A Systematic Review of Human Studies. Obes. Rev. 19 (12), 1719–1734. doi: 10.1111/obr.12750
    1. van der Lelie D., Taghavi S. (2020). COVID-19 and the Gut Microbiome: More Than a Gut Feeling. Msystems 5 (4), e00453–e00420. doi: 10.1128/mSystems.00453-20
    1. Venegas D., Marjorie K., Landskron G., González M., Quera R., Dijkstra G., et al. . (2019). Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and its Relevance for Inflammatory Bowel Diseases. Front. Immunol. 10, 277. doi: 10.3389/fimmu.2019.00277
    1. Walton G. E., Gibson G. R., Hunter K. A. (2021). Mechanisms Linking the Human Gut Microbiome to Prophylactic and Treatment Strategies for COVID-19. Br. J. Nutr. 126 (2), 219–227. doi: 10.1017/S0007114520003980
    1. Wang Z., Wang J., Cheng Y., Liu X., Huang Y. (2011). Secreted Factors From Bifidobacterium Animalis Subsp. Lactis Inhibit NF-κb-Mediated Interleukin-8 Gene Expression in Caco-2 Cells. Appl. Environ. Microbiol. 77 (22), 8171–8174. doi: 10.1128/AEM.06145-11
    1. Wang H., Wang H., Sun Y., Ren Z., Zhu W., Li A., et al. . (2021. a). Potential Associations Between Microbiome and COVID-19. Front. Med. 8. doi: 10.3389/fmed.2021.785496
    1. Wang H., Wang Y., Lu C., Qiu L., Song X., Jia H., et al. . (2021. b). The Efficacy of Probiotics in Patients With Severe COVID-19. Ann. Palliat. Med. 10 (12), 12374–12380. doi: 10.21037/apm-21-3373
    1. Wang B., Yao M., Lv L., Ling Z., Li L. (2017). The Human Microbiota in Health and Disease. Engineering 3 (1), 71–82. doi: 10.1016/J.ENG.2017.01.008
    1. Weiser J. N., Ferreira D. M., Paton J. C. (2018). Streptococcus Pneumoniae: Transmission, Colonization and Invasion. Nat. Rev. Microbiol. 16 (6), 355–367. doi: 10.1038/s41579-018-0001-8
    1. Wilks J., Golovkina T. (2012). Influence of Microbiota on Viral Infections. PloS Pathogens 8 (5), e1002681. doi: 10.1371/journal.ppat.1002681
    1. Wu Y., Cheng X., Jiang G., Tang H., Ming S., Tang L., et al. . (2021). Altered Oral and Gut Microbiota and its Association With SARS-CoV-2 Viral Load in COVID-19 Patients During Hospitalization. NPJ Biofilms Microbiomes 7 (1), 61. doi: 10.1038/s41522-021-00232-5
    1. Wu Y., Guo C., Tang L., Hong Z., Zhou J., Dong X., et al. . (2020). Prolonged Presence of SARS-CoV-2 Viral RNA in Faecal Samples. Lancet Gastroenterol. Hepatol. 5 (5), 434–435. doi: 10.1016/S2468-1253(20)30083-2
    1. Xue X., Mi Z., Wang Z., Pang Z., Liu H., Zhang F. (2021). High Expression of ACE2 on Keratinocytes Reveals Skin as a Potential Target for SARS-CoV-2. J. Invest. Dermatol. 141 (1), 206–209.e1. doi: 10.1016/j.jid.2020.05.087
    1. Xu Y., Li X., Zhu B., Liang H., Fang C., Gong Y., et al. . (2020). Characteristics of Pediatric SARS-CoV-2 Infection and Potential Evidence for Persistent Fecal Viral Shedding. Nat. Med. 26 (4), 502–505. doi: 10.1038/s41591-020-0817-4
    1. Yamamoto S., Saito M., Tamura A., Prawisuda D., Mizutani T., Yotsuyanagi H. (2021). The Human Microbiome and COVID-19: A Systematic Review. PloS One 16 (6), e0253293. doi: 10.1371/journal.pone.0253293
    1. Yeoh Y. K., Zuo T., Lui G. C., Zhang F., Liu Q., Li A. Y., et al. . (2021). Gut Microbiota Composition Reflects Disease Severity and Dysfunctional Immune Responses in Patients With COVID-19. Gut 70 (4), 698–706. doi: 10.1136/gutjnl-2020-323020
    1. Yildiz S., Mazel-Sanchez B., Kandasamy M., Manicassamy B., Schmolke M. (2018). Influenza A Virus Infection Impacts Systemic Microbiota Dynamics and Causes Quantitative Enteric Dysbiosis. Microbiome 6 (1), 9. doi: 10.1186/s40168-017-0386-z
    1. Yoshida N., Emoto T., Yamashita T., Watanabe H., Hayashi T., Tabata T., et al. . (2018). Bacteroides Vulgatus and Bacteroides Dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. Circulation 138 (22), 2486–2498. doi: 10.1161/CIRCULATIONAHA.118.033714
    1. Yu B., Dai C. -Q., Chen J., Deng L., Wu X. -I., Wu S., et al. . (2015). Dysbiosis of Gut Microbiota Induced the Disorder of Helper T Cells in Influenza Virus-Infected Mice. Hum. Vaccines Immunother. 11 (5), 1140–1146. doi: 10.1080/21645515.2015.1009805
    1. Zhang D., Li S., Wang N., Tan H. Y., Zhang Z., Feng Y. (2020). The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases. Front. Microbiol. 11, 301. doi: 10.3389/fmicb.2020.00301
    1. Zhang W., Zhu B., Xu J., Liu Y., Qiu E., Li Z., et al. . (2018). Bacteroides Fragilis Protects Against Antibiotic-Associated Diarrhea in Rats by Modulating Intestinal Defenses. Front. Immunol. 9 (1040). doi: 10.3389/fimmu.2018.01040
    1. Zheng L., Kelly C. J., Battista K. D., Schaefer R., Lanis J. M., Alexeev E. E., et al. . (2017). Microbial-Derived Butyrate Promotes Epithelial Barrier Function Through IL-10 Receptor-Dependent Repression of Claudin-2. J. Immunol. (Baltimore Md 1950) 199 (8), 2976–2984. doi: 10.4049/jimmunol.1700105
    1. Zhou P., Yang X. L., Wang X. G., Hu B., Zhang L., Zhang W., et al. . (2020). A Pneumonia Outbreak Associated With a New Coronavirus of Probable Bat Origin. Nature 579 (7798), 270–273. doi: 10.1038/s41586-020-2012-7
    1. Zhou Y., Zhang J., Zhang D., Ma W. L., Wang X. (2021). Linking the Gut Microbiota to Persistent Symptoms in Survivors of COVID-19 After Discharge. J. Microbiol. (Seoul Korea) 59 (10), 941–948. doi: 10.1007/s12275-021-1206-5
    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., et al. . (2020). A Novel Coronavirus From Patients With Pneumonia in China, 2019. New Engl. J. Med. 382 (8), 727–733. doi: 10.1056/NEJMoa2001017
    1. Zuo T., Liu Q., Zhang F., Lui G. C.-Y., Tso E. Y., Yeoh Y. K., et al. . (2021. a). Depicting SARS-CoV-2 Faecal Viral Activity in Association With Gut Microbiota Composition in Patients With COVID-19. Gut 70 (2), 276–284. doi: 10.1136/gutjnl-2020-322294
    1. Zuo T., Liu Q., Zhang F., Yeoh Y. K., Wan Y., Zhan H., et al. . (2021). Temporal Landscape of Human Gut RNA and DNA Virome in SARS-CoV-2 Infection and Severity. Microbiome 9 (1), 91. doi: 10.1186/s40168-021-01008-x
    1. Zuo T., Zhang F., Lui G. C. Y., Yeoh Y. K., Li A. Y. L., Zhan H., et al. . (2020. a). Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology 159 (3), 944–955.e8. doi: 10.1053/j.gastro.2020.05.048
    1. Zuo T., Zhan H., Zhang F., Liu Q., Tso E. Y. K., Lui G. C. Y., et al. . (2020. b). Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization Until Discharge. Gastroenterology 159 (4), 1302–1310.e5. doi: 10.1053/j.gastro.2020.06.048

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する